News & Updates

Pretoria, 08 November 2024 –The South African Health Products Regulatory Authority (SAHPRA) is concerned about the proliferation of falsified, compounded and substandard Glucagon-like Peptide (GLP-1)-containing products being made available to the public via websites, social media platforms and other informal channels. These pose a health...

Pretoria, 07 November 2024 – The South African Health Products Regulatory Authority (SAHPRA) encourages members of the public to always report any suspected side effects they may experience from taking medicines, vaccines and/or using medical devices, to help make medicines safer for everyone.  While humanity...

Pretoria, South Africa and Canberra, Australia, 07 October 2024 –The South African Health Products Regulatory Authority (SAHPRA) and the Australian Therapeutic Goods Administration (TGA) have signed a Memorandum of Understanding (MoU), which will strengthen collaboration between the two health product regulators. The MoU builds on the...

The South African Health Products Regulatory Authority (SAHPRA) has published four (4) Expression of Interests (EOIs) since 2023, and these have all been closed. Updates on EOIs: Ref: SAHPRA69092024 - Pharmaceutical Evaluations Management EOI closed on Friday, 26 April 2024. Appointments were made. Ref: SAHPRA20862023 - The EOI...

Pretoria, 22 July 2024 –The South African Health Products Regulatory Authority (SAHPRA) is disappointed with the unfounded fallacies and misrepresentation in circulation and churned out by some media organisations without verification, in what presents as a misinformation campaign devoid of any intent to rely on...